# Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

> **NCT00232596** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 306 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Retigabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00232596
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2016-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232596, "Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00232596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*